Panel · Use case · Brand & Marketing

Launch Claim Set Review.

LiveDocument Review

Which claims in this launch detail aid would a review committee challenge, and what support does each need?

DocumentA launch detail aid

LanesBrand, compliance, medical, regulatory

ReaderBrand and compliance leads

Not askedA rewrite

DepthStandard, four seats

Launch Claim Set Review is a ready-made use case for Brand & Marketing. It ships under the Document Review template.

For brand and commercial leads. You get an item-by-item ledger with verdicts and risk, the substantiation each claim needs, the required changes and what the review could not check. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Which claims in this launch detail aid would a review committee challenge, and what support does each need?

Who reviews

FDA lists the usual problems in promotion as overstated benefits, downplayed or omitted risks, unsupported claims, misrepresented study data and misleading comparisons. The seats review for each.

Seat	What it reviews	What it works from
Global Brand Lead	Whether the message is clear and what the claims imply to a prescriber.	The detail aid and its message research.
Global Commercial Compliance Officer	Fair balance, material facts and whether each claim has support.^{1U.S. Food and Drug Administration. Bad Ad Program (Office of Prescription Drug Promotion).}	FDA’s promotion program and the regulations.
Global Medical Affairs Director	Scientific accuracy and the fit of the data to the claim.	The cited publications.
Regulatory Strategist	Consistency with the approved labeling.^{1U.S. Food and Drug Administration. Bad Ad Program (Office of Prescription Drug Promotion).}	The labeling supplied.

What the review does

True is not enough. The ledger marks items that are accurate but omit a material fact or give undue emphasis, and states the change needed.^{1U.S. Food and Drug Administration. Bad Ad Program (Office of Prescription Drug Promotion).}

Every claim traces to a location. The substantiation table records the support offered for each claim and whether the panel could find it in the material supplied.^{2ProPharma Group. Medical, legal and regulatory (MLR) submission checklist.}

Superlatives and comparisons get extra scrutiny. Superiority, “first” or “only” claims are flagged for the evidence tier they need.

Recommended length

Standard

Four lanes bear on this document. Standard depth gives each a seat, the ledger and the substantiation table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the review makes

The review states what it assumes about the document and the material supplied, and says what each gap limits. Examples for this document:

The labeling supplied is current.
The references cited are the full set of support.
The audience is healthcare professionals.

Standards, guidance and sources

Framework

FDA Office of Prescription Drug Promotion, Bad Ad Program page.^{1U.S. Food and Drug Administration. Bad Ad Program (Office of Prescription Drug Promotion).}
ProPharma MLR submission checklist.^{2ProPharma Group. Medical, legal and regulatory (MLR) submission checklist.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any claim with no located support, any comparison without head-to-head data, and any verdict the seats could not agree on.

What arrives

The document under review
Overall recommendation
The review, by seat
Item-by-item ledger
Substantiation and evidence gaps
Required changes and conditions for approval
Rebuttal round
What this review could not check

What it will not do

This is analyst judgment from AI specialists and not a regulatory, medical or legal sign-off. It cannot check original data or the approved label, and the decision stays with you.

It does not replace the company’s promotional review.

It is analyst judgment from AI specialists and not a regulatory, medical or legal sign-off.

It does not rewrite the document. It states the change and leaves the writing to the author.

It does not check original data or the approved label held by the company. Those checks need a real reviewer.

References

[1] U.S. Food and Drug Administration. Bad Ad Program (Office of Prescription Drug Promotion). Read in the template research of 9 October 2026.
[2] ProPharma Group. Medical, legal and regulatory (MLR) submission checklist. Consultancy page; practitioner source.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.